ENG/中
老虎证券
市场
行情
24/7新闻
产品
Cash Boost账户
期权
A股通
港股
固定票息票据
美股
ETF
基金超市
美国国债
新加坡股
期货
Tiger BOSS Debit Card
老虎钱袋子
功能
经纪人
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登录
立即注册
Toggle
港股
详情
本页面由Tiger Trade Technology Pte. Ltd.提供服务
生物医药B类股
530.725
-2.123
-0.40%
手动刷新
涨家数:
8
跌家数:
24
平家数:
1
市盈率:
- -
高:
543.539
开:
532.796
低:
528.924
收:
532.848
成交量:
6,453.45万
成交额:
15.55亿
市值:
3,389.61亿
流通市值:
3,020.29亿
数据加载中...
总览
新闻资讯
港股异动 | 科济药业-B(02171.HK)再涨超4% 旗下通用型CAR-T接连获批 恺力美纳入百万医疗险
智通财经
·
54分钟前
创新药“多点开花” “癌症慢病化”深刻影响医药产业
新华财经
·
2小时前
港股异动 | 微创心通-B(02160)涨近5% 预计上半年亏损不高于2500万美元 全球心律管理业务持续稳定增长
智通财经
·
2小时前
港股异动 | 微创心通-B(02160.HK)涨近5% 预计上半年亏损不高于2500万美元 全球心律管理业务持续稳定增长
智通财经
·
2小时前
再鼎医药午前涨超5% 公司自主研发资产正逐步进入临床价值验证阶段
新浪港股
·
2小时前
出海提速+中报兑现+AI赋能,创新药板块景气修复延续!T+0恒生创新药ETF华泰柏瑞(520500)年内份额增长77%
新浪基金
·
3小时前
医药调研热度超越半导体!创新药回调,华宝基金港股通创新药ETF失守半年线!CXO韧性十足,药明系逆市飘红
新浪基金
·
3小时前
港股异动 | 再鼎医药(09688.HK)再涨超5% 核心管线迎来密集催化 创新将成下一阶段增长核心动力
智通财经
·
3小时前
科济药业-B(02171)股价上升5.023%,现价港币$15.89
阿斯达克财经
·
3小时前
创新药人气股,2分钟直线涨停
第一财经
·
4小时前
国家药监局批准2款创新药上市
南方财经网
·
4小时前
港股开盘 | 恒指低开0.6% 黄金股走强 再鼎医药(09688)涨超8%
智通财经
·
5小时前
港股开盘|港股开盘持平;医药股走强;再鼎医药涨超8%
港股开盘
·
5小时前
指数震荡分化观望情绪升温,聚焦医药与算力链内部的轮动机会
中金财经
·
5小时前
再鼎医药(09688)出现大手卖出77.63万股,成交价$20.02,涉资1.554千万
阿斯达克财经
·
5小时前
微创心通-B:预计上半年净亏损不超2500万美元
财中社
·
5小时前
住友制药株式会社: 做空机构哥谭市研究(Gotham City Research,简称GCR) 于2026年8月3日发布
格隆汇
·
6小时前
盈利走强 产品放量 出海破局——从业绩预告看创新药行业发展
经济参考报
·
11小时前
亏损持续、现金紧张、对赌高悬普祺医药再次向港交所递交IPO申请
滚动播报
·
11小时前
八月新基供给走弱 医药板块获逆向布局
滚动播报
·
11小时前
更多
{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/BK1574/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物医药B类股","latestPrice":530.7247,"timestamp":1786516528439,"preClose":532.84753,"halted":0,"volume":64535473,"delay":0,"changeRate":-0.003984,"floatShares":0,"shares":0,"eps":0,"marketStatus":"交易中","change":-2.122864,"latestTime":"08-12 14:35:28","open":532.796,"high":543.53937,"low":528.924,"amount":1554658986,"amplitude":0.027429,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1786522200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1786498200000,1786507200000],[1786510800000,1786521600000]],"pbRate":4.320612,"peRate":-81.172646,"turnoverRate":0.002343,"increases":8,"decrements":24,"flats":1,"marketCap":338961408112,"floatMarketCap":302028914832},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":543.53937,"amplitude":0.027429,"preClose":532.84753,"low":528.924,"pbRate":"4.320612","latestPrice":530.7247,"volume":64534473,"delay":0,"open":532.796,"prevYearClose":556.26263,"prevWeekClose":516.343,"prevMonthClose":473.313,"prevQuarterClose":453.519,"fiveDayClose":485.719,"twentyDayClose":525.18,"sixtyDayClose":579.587,"secType":"PLATE","market":"HK","turnoverRate":0.002343,"peRate":-81.172646,"marketCap":338961408112,"floatMarketCap":302028914832,"timestamp":1786516519578,"nameCN":"生物医药B类股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":8,"down":24,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2658926656","title":"港股异动 | 科济药业-B(02171.HK)再涨超4% 旗下通用型CAR-T接连获批 恺力美纳入百万医疗险","url":"https://stock-news.laohu8.com/highlight/detail?id=2658926656","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658926656?lang=zh_cn&edition=fundamental","pubTime":"2026-08-12 13:42","pubTimestamp":1786513321,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02171","BK1574","BK1587","BK1161","BK1585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658692341","title":"创新药“多点开花” “癌症慢病化”深刻影响医药产业","url":"https://stock-news.laohu8.com/highlight/detail?id=2658692341","media":"新华财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658692341?lang=zh_cn&edition=fundamental","pubTime":"2026-08-12 12:14","pubTimestamp":1786508074,"startTime":"0","endTime":"0","summary":"国家药监局最新数据显示,今年上半年我国批准38个1类创新药上市,其中11个新靶点、新机制药物全部为国产自主研发。在这11个具备全球首创潜力的创新药中,抗肿瘤药物占4个。随着更多抗肿瘤新药获批上市,靶向、免疫、细胞治疗等新疗法不断取得突破,越来越多癌症患者的生存周期从“按周、按月计算”拉长至“按年甚至十年计算”。医学技术进步推进癌症慢病化,也对医药产业发展产生显著影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608123839000216.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608123839000216.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LNGR","BK1161","06978","159992","BK1574","MEDX","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658923868","title":"港股异动 | 微创心通-B(02160)涨近5% 预计上半年亏损不高于2500万美元 全球心律管理业务持续稳定增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2658923868","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658923868?lang=zh_cn&edition=fundamental","pubTime":"2026-08-12 11:55","pubTimestamp":1786506906,"startTime":"0","endTime":"0","summary":"消息面上,微创心通公告,由于集团于2025年12月19日完成收购心律管理业务,心律管理业务于截至2026年6月30日止六个月首次全部合并入本集团财务报表。根据目前可得最新资料的评估,预期报告期取得收入不低于1.53亿美元,净亏损不高于2500万美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478860.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK4588","BK1239","BK1100","BK1574","BK4585","HART","02160","VXUS","BK1225","KCAI","02918"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658238509","title":"港股异动 | 微创心通-B(02160.HK)涨近5% 预计上半年亏损不高于2500万美元 全球心律管理业务持续稳定增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2658238509","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658238509?lang=zh_cn&edition=fundamental","pubTime":"2026-08-12 11:55","pubTimestamp":1786506906,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1100","BK1225","02918","BK1574","02160","BK1583","BK1239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658081928","title":"再鼎医药午前涨超5% 公司自主研发资产正逐步进入临床价值验证阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2658081928","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658081928?lang=zh_cn&edition=fundamental","pubTime":"2026-08-12 11:45","pubTimestamp":1786506300,"startTime":"0","endTime":"0","summary":"模拟交易客户端再鼎医药早盘一度涨超11%,绩后股价已累涨超三成。截至发稿,股价上涨5.13%,现报19.48港元,成交额3.59亿港元。再鼎医药今年二季度实现总收入为1.063亿美元,产品收入净额为1.058亿美元,环比增长11%,得益于则乐的稳定表现以及艾加莫德的销量持续增长。中信建投指出,公司自主研发资产正逐步进入临床价值验证阶段,核心自研管线有望于年内迎来密集数据读出及关键研发进展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-08-12/doc-inimzqcr3698280.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","BK1574","BK1588","BK1161","09688","BK4526","BK4531","BK4588","ZLAB","BK4548","LU2488822045.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658447928","title":"出海提速+中报兑现+AI赋能,创新药板块景气修复延续!T+0恒生创新药ETF华泰柏瑞(520500)年内份额增长77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658447928","media":"新浪基金","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658447928?lang=zh_cn&edition=fundamental","pubTime":"2026-08-12 11:33","pubTimestamp":1786505580,"startTime":"0","endTime":"0","summary":"下半年以来,创新药板块的修复行情持续推进。作为当前A股市场仅有的跟踪恒生创新药指数的ETF,恒生创新药ETF华泰柏瑞今年以来合计“吸金”14.45亿元,助推基金份额与规模分别攀升至22.10亿份、32.30亿元,较年初分别增长77%、67%,流动性优势较突出。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-08-12/doc-inimzqcv4064339.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["ARTY","QTOC","LNGR","AGIX","06978","BK1161","CHAT","159992","BK1574","AIPO","520500","MEDX","IBBQ","VTHR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658288069","title":"医药调研热度超越半导体!创新药回调,华宝基金港股通创新药ETF失守半年线!CXO韧性十足,药明系逆市飘红","url":"https://stock-news.laohu8.com/highlight/detail?id=2658288069","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658288069?lang=zh_cn&edition=fundamental","pubTime":"2026-08-12 11:02","pubTimestamp":1786503720,"startTime":"0","endTime":"0","summary":"业绩兑现叠加AI制药概念加持,CXO韧性十足,药明生物、药明康德、药明合联逆市飘红,金斯瑞生物科技续涨逾1%。港股通创新药龙头股批量飘绿,百济神州跌2%止步6连阳,翰森制药跌逾3%;再鼎医药延续涨势,股价创年内新高。100%创新药研发标的——港股通创新药ETF华宝冲高回落,现跌1%再失半年线。8月以来,创新药及产业链利好密集,“吃药”行情持续上演。同期医药生物行业的市场关注度大幅攀升。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-12/doc-inimzqcp6895872.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["PSI","VGT","BK4588","CXO","NBDS","BK1515","SOXY","USD","SMH","TECY","MEDX","EIS","CHPY","SSG","SMHU","SOXL","BK4535","LNGR","SMHX","IBBQ","CHPS","159938","SOXQ","FTXL","159316","FWD","BK1574","WX","SOXX","XSD","BK1161","BK4585","MQQQ","FLHK","09939","159992","06978","159582","TEKX","CWC","SOXS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658407879","title":"港股异动 | 再鼎医药(09688.HK)再涨超5% 核心管线迎来密集催化 创新将成下一阶段增长核心动力","url":"https://stock-news.laohu8.com/highlight/detail?id=2658407879","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658407879?lang=zh_cn&edition=fundamental","pubTime":"2026-08-12 10:53","pubTimestamp":1786503210,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","BK1161","BK1588","LU2488822045.USD","09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658928372","title":"科济药业-B(02171)股价上升5.023%,现价港币$15.89","url":"https://stock-news.laohu8.com/highlight/detail?id=2658928372","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658928372?lang=zh_cn&edition=fundamental","pubTime":"2026-08-12 10:53","pubTimestamp":1786503180,"startTime":"0","endTime":"0","summary":"[上升股]科济药业-B(02171) 股价在上午10:52比前收市价上升5.023%,现股价为港币$15.89。至目前为止,今日最高价为$15.89,而最低价为$15.18。总成交量为102.6万股,总成交金额为港币$1.609千万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180112133338093_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180112133338093_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2608121605/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2608121605/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02171","BK1587","BK1585","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658409069","title":"创新药人气股,2分钟直线涨停","url":"https://stock-news.laohu8.com/highlight/detail?id=2658409069","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658409069?lang=zh_cn&edition=fundamental","pubTime":"2026-08-12 10:21","pubTimestamp":1786501260,"startTime":"0","endTime":"0","summary":"此前在8月10日,百花医药发布股票交易异常波动公告称,公司2026年第一季度实现营业收入6718.29万元,同比下降30.68%,归母净利润664.27万元,同比下降67.94%。公司股价短期内波动较大,公司股票目前已累积较大二级市场交易风险,未来存在快速下跌的风险。创新药板块中,誉衡药业涨超9%,万邦医药涨超8%,泓博医药、昆药集团、陇神戎发、美迪西跟涨。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/wm/2026-08-12/doc-inimzivt3775229.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-08-12/doc-inimzivt3775229.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","LNGR","IBBQ","BK1574","06978","159992","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658866940","title":"国家药监局批准2款创新药上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2658866940","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658866940?lang=zh_cn&edition=fundamental","pubTime":"2026-08-12 09:51","pubTimestamp":1786499460,"startTime":"0","endTime":"0","summary":"南方财经8月12日电,近日,国家药品监督管理局通过优先审评审批程序,附条件批准药捷安康(南京)科技股份有限公司申报的1类创新药替恩戈替尼片(商品名称:捷恩泰)上市,该药用于既往接受过系统性治疗和FGFR抑制剂治疗,且具有成纤维细胞生长因子受体(FGFR)2融合或重排的晚期、转移性或不可手术切除的胆管癌成人患者的治疗。该药品上市为患者提供了新的治疗选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608123838902271.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608123838902271.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159992","LNGR","BK1161","MEDX","IBBQ","06978","IPOS","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658947545","title":"港股开盘 | 恒指低开0.6% 黄金股走强 再鼎医药(09688)涨超8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658947545","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658947545?lang=zh_cn&edition=fundamental","pubTime":"2026-08-12 09:29","pubTimestamp":1786498159,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,8月12日,恒生指数低开0.6%,报25498.39点;恒生科技指数跌0.8%,报4785.75点;国企指数跌0.57%,报8479.60点。大市盘前成交21.70亿港元。黄金股走强,紫金黄金国际涨超2%,中国黄金国际涨超2%,灵宝黄金涨超2%,老铺黄金涨近2%,山东黄金涨超1%。医药股走强,再鼎医药涨超8%,药明合联涨超1%。受再鼎医药隔夜美股涨超10%带动。受隔夜美股三大指数全线收跌、中概股金龙指数跌2.94%拖累,港股今日低开。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478792.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1588","BK1574","LU2488822045.USD","ZLAB","09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168242546","title":"港股开盘|港股开盘持平;医药股走强;再鼎医药涨超8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1168242546","media":"港股开盘","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168242546?lang=zh_cn&edition=fundamental","pubTime":"2026-08-12 09:21","pubTimestamp":1786497715,"startTime":"0","endTime":"0","summary":"盘面上,生物医药、资源金属及AI概念活跃,带动个股分化上行;在线娱乐、教育等消费服务类个股则出现回吐,市场风格短线偏向防御与结构性轮动。大型科技股延续弱势,多数回调逾0.5%,仅理想汽车小幅飘红;阿里、腾讯、京东等均低开,或受隔夜美股科技股走软及机构获利了结影响。盘面亮点集中在生物医药与资源股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","BK4531","ZLAB","09688","VXUS","BK1515","BK4548","BK1161","BK1588","BK4526","BK4588","KCAI","BK1574","09939","BK4585","159938","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658478149","title":"指数震荡分化观望情绪升温,聚焦医药与算力链内部的轮动机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2658478149","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658478149?lang=zh_cn&edition=fundamental","pubTime":"2026-08-12 09:20","pubTimestamp":1786497609,"startTime":"0","endTime":"0","summary":" 昨日市场全天震荡分化,三大指数涨跌不一,创业板指小幅收红。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/zldongxiang/20260812/32332314.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","BK1574","159938","09939","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658947954","title":"再鼎医药(09688)出现大手卖出77.63万股,成交价$20.02,涉资1.554千万","url":"https://stock-news.laohu8.com/highlight/detail?id=2658947954","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658947954?lang=zh_cn&edition=fundamental","pubTime":"2026-08-12 09:20","pubTimestamp":1786497600,"startTime":"0","endTime":"0","summary":"[大手成交]再鼎医药(09688)在上午09:20出现大手卖出,成交量为77.63万,成交价为港币$20.02,涉资1.554千万。至目前为止,股价升8.041%,今日最高价为$20.02,而最低价为$20.02,总成交量为77.63万股,总成交金额港币$1.554千万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126132515779_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126132515779_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT26081238/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT26081238/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1588","BK1574","LU2488822045.USD","BK1161","09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658194263","title":"微创心通-B:预计上半年净亏损不超2500万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2658194263","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658194263?lang=zh_cn&edition=fundamental","pubTime":"2026-08-12 08:40","pubTimestamp":1786495200,"startTime":"0","endTime":"0","summary":"8月11日,微创心通-B(02160)发布公告,由于公司于2025年12月19日完成收购心律管理业务,该业务于2026年上半年首次全部合并入公司财务报表。根据初步审阅,公司预计2026年上半年录得收入不低于1.53亿美元,净亏损不高于2500万美元。在报告期内,公司全球心律管理业务持续稳定增长,其中中国市场起搏器植入量录得双位数增幅。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608123838567556.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608123838567556.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1225","02160","BK1583","BK1239","BK1574","02918","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658412429","title":"住友制药株式会社: 做空机构哥谭市研究(Gotham City Research,简称GCR) 于2026年8月3日发布","url":"https://stock-news.laohu8.com/highlight/detail?id=2658412429","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658412429?lang=zh_cn&edition=fundamental","pubTime":"2026-08-12 07:54","pubTimestamp":1786492497,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1574","01477","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658691050","title":"盈利走强 产品放量 出海破局——从业绩预告看创新药行业发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2658691050","media":"经济参考报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658691050?lang=zh_cn&edition=fundamental","pubTime":"2026-08-12 02:44","pubTimestamp":1786473854,"startTime":"0","endTime":"0","summary":"创新药板块近期持续走强。截至8月11日收盘,万邦医药涨20%,报70.39元/股,年内累计涨幅高达149%;百花医药走出6连板,收盘报12.75元/股,近5日涨幅60.98%;振东制药大涨14.26%,亚泰集团、甘李药业、哈药股份同步封板,板块做多情绪持续升温。二级市场热度涌动的背后,是创新药产业基本面迎来实质性改善。2026年上半年,国内创新药行业迎来业绩兑现窗口。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608123838283832.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608123838283832.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LNGR","IBBQ","06978","BK1574","159992","MEDX","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658594137","title":"亏损持续、现金紧张、对赌高悬普祺医药再次向港交所递交IPO申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2658594137","media":"滚动播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658594137?lang=zh_cn&edition=fundamental","pubTime":"2026-08-12 02:36","pubTimestamp":1786473360,"startTime":"0","endTime":"0","summary":"近日,北京普祺医药科技股份有限公司再次向港交所递交上市申请。在此前港股申请失效后,普祺医药重启IPO闯关。若本次IPO融资未能顺利完成,公司持续现金消耗或将引发经营危机。对赌契约高悬招股书显示,根据相关投资协议约定,公司控股股东之一也是普祺医药的创始人、董事长兼总经理李雨亮,向多名机构投资者授予多项特殊股东权利,主要包括反摊薄权与赎回权。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-08-12/doc-inimysxx7185762.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IPOS","BK1515","REDS","BK4127","BK1574","KCE","159938","09939","BK1161","HEXmain","FRHC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658413249","title":"八月新基供给走弱 医药板块获逆向布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2658413249","media":"滚动播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658413249?lang=zh_cn&edition=fundamental","pubTime":"2026-08-12 02:36","pubTimestamp":1786473360,"startTime":"0","endTime":"0","summary":"从行业特征来看,多家公募以行业主题发起式基金对细分赛道进行快速布局,其中,调整充分、估值处于低位的医药板块获得重点关注。公募机构借助发起式基金的低门槛优势,加速布局前期调整充分、估值回归合理区间的赛道,其中医药板块因调整时间较长、基本面韧性突出,已成为逆向投资的重点方向。截至目前,多只创新药ETF自年内低点反弹逾20%,合计吸金超百亿元;此外,还有部分医药主题主动权益基金最高涨幅超30%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-08-12/doc-inimysyf4300731.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","159938","BK1515","09939","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":17,"pageCount":1,"totalSize":328,"code":"91000000","status":"200"}]}}